Unmethylated CpG dinucleotides present in bacterially-derived plasmid DNA are potent triggers of innate immunity via Toll-like receptor 9 (TLR9). For viral vector production, where plasmids serve as the primary starting material for transgenes and helper functions, this immunostimulation can compromise vector safety and efficacy. Proactive plasmid design, focused on the systematic reduction of CpG motifs through in silico analysis and sequence optimization, is a primary component of a strong CMC strategy. This approach mitigates downstream inflammatory responses, improves vector persistence, and supports a more predictable safety profile for AAV, lentivirus, and adenovirus programs.

Proactive Plasmid Design to Control Vector Immunogenicity

The plasmid DNA used to generate viral vectors is a biologically active component that directly influences the host response to the final product. The presence of unmethylated CpG motifs within the plasmid backbone or the transgene cassette itself can activate an innate immune cascade, recruiting key effector cells like macrophages and NK cells. This initial inflammatory event can shape the subsequent adaptive immune response, potentially limiting the durability of the therapy. As observed in studies of adenoviral vectors, the innate immune system’s reaction to vector components is a primary driver of acute, localized pathology (PMID: 15714134).

Mitigating this response begins at the earliest possible stage: plasmid design. This requires treating immunogenicity as a fundamental design parameter, addressed through sequence engineering rather than as a downstream purification challenge.

Our approach to vector development incorporates this principle from the outset. We employ a rigorous process for plasmid optimization that includes:

• Sequence-Level Analysis: Comprehensive in silico screening of all plasmid sequences to identify and map CpG hotspots.

• Codon Optimization: Modifying the transgene sequence to remove CpG motifs while maintaining the integrity of the encoded amino acid sequence and optimizing for expression in human cells.

• Backbone Engineering: Selecting or designing plasmid backbones that are inherently low in CpG content to minimize the overall immunostimulatory load.

This level of upfront engineering provides a stronger foundation for the entire development program. By de-risking the starting materials, we create a more predictable path toward IND. This work provides strategic design guidance accelerating development lifecycles.

This proactive approach to plasmid design is a core element of our CMC consulting services. It aligns with our broader philosophy of building robust, phase-appropriate processes that give our partners confidence as they move toward the clinic. This commitment to quality and scientific rigor has contributed to a 100% IND approval success rate for programs we have supported since 2019, with the Franklin Biolabs brand itself having launched in 2024 to carry this legacy forward.